On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

and Portugal. In addition, he is the managing director of Alnylam Netherlands. Murthy is also the head of market access, pricing, and public policy, overseeing the company’s interactions with ...

Alnylam Pharma (ALNY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on the ...

Don't Miss our Black Friday Offers: Mani Foroohar has given his Hold rating due to a combination of factors influencing Alnylam Pharma’s outlook. The FDA’s acceptance of the supplemental New ...

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the label expansion of Amvuttra (vutrisiran) for review to treat ATTR ...

Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals ALNY revealed 19 unusual trades. Delving into the ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...

Vutisiran, an RNA-silencing therapy being developed by Alnylam, is actually expected to surpass Attruby in sales: Analysts forecast vutisiran to ultimately reach $7 billion annually. But the ...

Would you like to live in paradise? The perfect temperature, spectacular beaches and enchanting little villages ... what more could you ask for? Discover the magical beauty of the Azores and Madeira!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper ...